Open Access

Prognostic and clinicopathological value of melanoma-associated antigen D4 in patients with glioma

  • Authors:
    • Jun Yan
    • Jing Wen
    • Zong‑Dang Wei
    • Xi‑Sheng Li
    • Ping Li
    • Shao‑Wen Xiao
  • View Affiliations

  • Published online on: January 26, 2018     https://doi.org/10.3892/ol.2018.7884
  • Pages: 4151-4160
  • Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The aim of the present study was to evaluate the clinical importance of melanoma‑associated antigen D4 (MAGE‑D4) expression in glioma, and to identify it as a valuable prognostic biomarker and therapeutic target. To achieve this, the expression of MAGE‑D4 protein in 124 tumor tissues from patients with glioma was measured using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and immunohistochemistry (IHC), and the associations between MAGE‑D4expression and clinicopathological factors were evaluated. The survival analysis demonstrated the significant prognostic value of MAGE‑D4 in glioma using follow‑up data. RT‑qPCR and IHC analysis confirmed that MAGE‑D4 mRNA and protein expression levels were significantly increased in glioma tissues compared with those in normal brain tissues. The present study demonstrated that the percentage of glioma tissues with high expression of MAGE‑D4 mRNA was 67.74%, and the percentage positive for MAGE‑D4 protein expression was 78.23%. All patients with high MAGE‑D4 expression in cancerous tissues experienced significantly reduced median overall survival (OS; 18.00 vs. 33.29 months; P<0.001) and recurrence‑free survival (RFS; 12.7 vs. 28.3 months; P<0.001) times compared with those with low MAGE‑D4 expression. In the patients with lower grade glioma [World Health Organization (WHO), I‑II], similar results were obtained for the OS (26.11 vs. 57.85 months; P=0.013) and RFS (22.7 vs. 55.3 months; P=0.010) times; however, in patients with high‑grade glioma (WHO, III‑IV), there were no significant differences between high and low MAGE‑D4 expression levels with regard to OS and RFS times (P>0.05). Multivariate analysis indicated that high MAGE‑D4 protein expression was an important independent prognostic factor for patients with glioma (hazard ratio, 2.384; P=0.005), and was significantly associated with higher grade glioma (P<0.001). These results indicated that MAGE‑D4 may be a potential biomarker for glioma and an important prognostic factor for patients with new or recurring glioma.

References

1 

Huse JT and Holland EC: Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Thomas AA, Brennan CW, DeAngelis LM and Omuro AM: Emerging therapies for glioblastoma. JAMA Neurol. 71:1437–1444. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Lee KH, Ahn EJ, Oh SJ, Kim O, Joo YE, Bae JA, Yoon S, Ryu HH, Jung S, Kim KK, et al: KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers. Oncotarget. 6:3240–3253. 2015.PubMed/NCBI

4 

Diksin M, Smith SJ and Rahman R: The molecular and phenotypic basis of the glioma invasive perivascular niche. Int J Mol Sci. 18:pii: E23422017. View Article : Google Scholar

5 

Guo L, Sang M, Liu Q, Fan X, Zhang X and Shan B: The expression and clinical significance of melanoma-associated antigen-A1, -A3 and -A11 in glioma. Oncol Lett. 6:55–62. 2013. View Article : Google Scholar : PubMed/NCBI

6 

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI

7 

Lee AK and Potts PR: A comprehensive guide to the MAGE family of ubiquitin ligases. J Mol Biol. 429:1114–1142. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T and Lucas S: An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61:5544–5551. 2001.PubMed/NCBI

9 

Krämer BF, Schoor O, Krüger T, Reichle C, Müller M, Weinschenk T, Hennenlotter J, Stenzl A, Rammensee HG and Stevanovic S: MAGED4-expression in renal cell carcinoma and identification of an HLA-A'25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol Ther. 4:943–948. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Ma QY, Pang LW, Chen ZM, Zhu YJ, Chen G and Chen J: The significance of MAGED4 expression in non-small cell lung cancer as analyzed by real-time fluorescence quantitative PCR. Oncol Lett. 4:733–738. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J and O'Driscoll L: MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Cancer. 130:1991–2002. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Chong CE, Lim KP, Gan CP, Marsh CA, Zain RB, Abraham MT, Prime SS, Teo SH, Silvio Gutkind J, Patel V and Cheong SC: Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. Cancer Lett. 321:18–26. 2012. View Article : Google Scholar : PubMed/NCBI

13 

Takami H, Kanda M, Oya H, Hibino S, Sugimoto H, Suenaga M, Yamada S, Nishikawa Y, Asai M, Fujii T, et al: Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. J Surg Oncol. 108:557–562. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Oya H, Kanda M, Takami H, Hibino S, Shimizu D, Niwa Y, Koike M, Nomoto S, Yamada S, Nishikawa Y, et al: Overexpression of melanoma-associated antigen D4 is an independent prognostic factor in squamous cell carcinoma of the esophagus. Dis Esophagus. 28:188–195. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Zhang QM, He SJ, Shen N, Luo B, Fan R, Fu J, Luo GR, Zhou SF, Xiao SW and Xie XX: Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target. Int J Clin Exp Pathol. 7:3918–3927. 2014.PubMed/NCBI

16 

He SJ, Gu YY, Yu L, Luo B, Fan R, Lin WZ, Lan XW, Lin YD, Zhang QM, Xiao SW and Xie XX: High expression and frequently humoral immune response of melanoma-associated antigen D4 in glioma. Int J Clin Exp Pathol. 7:2350–2360. 2014.PubMed/NCBI

17 

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Zhang QM, Shen N, Xie S, Bi SQ, Luo B, Lin YD, Fu J, Zhou SF, Luo GR, Xie XX and Xiao SW: MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2′-deoxycytidine treatment. Asian Pac J Cancer Prev. 15:3495–3501. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Sasaki M, Nakahira K, Kawano Y, Katakura H, Yoshimine T, Shimizu K, Kim SU and Ikenaka K: MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res. 61:4809–4814. 2001.PubMed/NCBI

20 

Parney IF, Hao C and Petruk KC: Glioma immunology and immunotherapy. Neurosurgery. 46:778–792. 2000. View Article : Google Scholar : PubMed/NCBI

21 

Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 16:111–120. 1980. View Article : Google Scholar : PubMed/NCBI

22 

Ito S, Kawano Y, Katakura H, Takenaka K, Adachi M, Sasaki M, Shimizu K, Ikenaka K, Wada H and Tanaka F: Expression of MAGE-D4, a novel MAGE family antigen, is correlated with tumor-cell proliferation of non-small cell lung cancer. Lung Cancer. 51:79–88. 2006. View Article : Google Scholar : PubMed/NCBI

23 

Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA and Sood AK: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 10:5145–5150. 2004. View Article : Google Scholar : PubMed/NCBI

24 

Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI

25 

Han ZG, Jiang WG, Hiscox S, Hallett MB, Isoai A and Mansel RE: Inhibition of motility and invasion of human lung cancer cells by invasion inhibiting factor 2. Surg Oncol. 5:77–84. 1996. View Article : Google Scholar : PubMed/NCBI

26 

Zhao W, Zhou Y, Xu H, Cheng Y and Kong B: Snail family proteins in cervical squamous carcinoma: Expression and significance. Clin Invest Med. 36:E223–E233. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Song X, Zhang W, Zhang Y, Zhang H, Fu Z, Ye J, Liu L, Song X and Wu Y: Expression of semaphorin 3A and neuropilin 1 with clinicopathological features and survival in human tongue cancer. Med Oral Patol Oral Cir Bucal. 17:e962–e968. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL and Jiang HB: Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: Correlation with the clinicopathological features and patient outcome. Mod Pathol. 23:213–224. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Szopa W, Burley TA, Kramer-Marek G and Kaspera W: Diagnostic and therapeutic biomarkers in glioblastoma: Current status and future perspectives. Biomed Res Int. 2017:80135752017. View Article : Google Scholar : PubMed/NCBI

30 

Cheong SC, Chandramouli GV, Saleh A, Zain RB, Lau SH, Sivakumaren S, Pathmanathan R, Prime SS, Teo SH, Patel V and Gutkind JS: Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. Oral Oncol. 45:712–719. 2009. View Article : Google Scholar : PubMed/NCBI

31 

Tsai JR, Chong IW, Chen YH, Yang MJ, Sheu CC, Chang HC, Hwang JJ, Hung JY and Lin SR: Differential expression profile of MAGE family in non-small-cell lung cancer. Lung Cancer. 56:185–192. 2007. View Article : Google Scholar : PubMed/NCBI

32 

Mathieu MG, Linley AJ, Reeder SP, Badoual C, Tartour E, Rees RC and McArdle SE: HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. Cancer Immun. 10:22010.PubMed/NCBI

33 

Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM and Beer DG: Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 1:304–313. 2002. View Article : Google Scholar : PubMed/NCBI

34 

Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, et al: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys. 36:549–556. 1996. View Article : Google Scholar : PubMed/NCBI

35 

Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D and Shaw EG: Validation of EORTC prognostic factors for adults with low-grade glioma: A report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 81:218–224. 2011. View Article : Google Scholar : PubMed/NCBI

36 

Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H and Figarella-Branger D: Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol. 24:381–388. 1998. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yan, J., Wen, J., Wei, Z., Li, X., Li, P., & Xiao, S. (2018). Prognostic and clinicopathological value of melanoma-associated antigen D4 in patients with glioma. Oncology Letters, 15, 4151-4160. https://doi.org/10.3892/ol.2018.7884
MLA
Yan, J., Wen, J., Wei, Z., Li, X., Li, P., Xiao, S."Prognostic and clinicopathological value of melanoma-associated antigen D4 in patients with glioma". Oncology Letters 15.4 (2018): 4151-4160.
Chicago
Yan, J., Wen, J., Wei, Z., Li, X., Li, P., Xiao, S."Prognostic and clinicopathological value of melanoma-associated antigen D4 in patients with glioma". Oncology Letters 15, no. 4 (2018): 4151-4160. https://doi.org/10.3892/ol.2018.7884